Thakkar Roopal's most recent trade in Abbvie Inc was a trade of 4,678 Common Stock, $0.01 par value done at an average price of $205.0 . Disclosure was reported to the exchange on Feb. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie | Roopal Thakkar | EVP, R&D and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 4,678 | 42,276 (0%) | 0% | 205.0 | 959,084 | Common Stock, $0.01 par value |
| AbbVie | Roopal Thakkar | EVP, R&D and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 25,000 | 25,000 | - | - | Option (Right to buy) | |
| AbbVie | Roopal Thakkar | EVP, R&D and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 3,595 | 39,994 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Roopal Thakkar | EVP, R&D and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 3,348 | 46,954 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Roopal Thakkar | EVP, R&D and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 2,138 | 43,606 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Roopal Thakkar | EVP, R&D and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 1,474 | 41,468 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Roopal Thakkar | SVP, CMO, GLOBAL THERAPEUTICS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 178.99 per share. | 28 Feb 2024 | 4,914 | 23,259 (0%) | 0% | 179.0 | 879,557 | Common Stock, $0.01 par value |
| AbbVie | Thakkar Roopal | SVP, CMO, GLOBAL THERAPEUTICS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 13,868 | 13,868 | - | - | Option (Right to buy) | |
| AbbVie | Roopal Thakkar | EVP, R&D and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 13,868 | 13,868 | - | - | Option (Right to buy) | |
| AbbVie | Thakkar Roopal | SVP, CMO, GLOBAL THERAPEUTICS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 8,022 | 18,399 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Roopal Thakkar | EVP, R&D and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 5,900 | 36,125 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Roopal Thakkar | SVP, CMO, GLOBAL THERAPEUTICS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 5,792 | 28,173 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Roopal Thakkar | EVP, R&D and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 2,140 | 41,313 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Thakkar Roopal | SVP, CMO, GLOBAL THERAPEUTICS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 2,138 | 20,537 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Thakkar Roopal | SVP, CMO, GLOBAL THERAPEUTICS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,844 | 22,381 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Roopal Thakkar | EVP, R&D and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,572 | 37,697 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Roopal Thakkar | EVP, R&D and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,476 | 39,173 (0%) | 0% | 0 | Common Stock, $0.01 par value |